{"name":"Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.","slug":"zhaoke-guangzhou-ophthalmology-pharmaceutical-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Ophthalmology","slug":"ophthalmology","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"oncology","drugs":[{"name":"Hypromellose Eye Drop","genericName":"Hypromellose Eye Drop","slug":"hypromellose-eye-drop","indication":"Dry eye syndrome / Keratoconjunctivitis sicca","status":"marketed"},{"name":"CsA Ophthalmic Gel","genericName":"CsA Ophthalmic Gel","slug":"csa-ophthalmic-gel","indication":"Dry eye disease (moderate to severe)","status":"phase_3"},{"name":"CsA-PG Ophthalmic Gel","genericName":"CsA-PG Ophthalmic Gel","slug":"csa-pg-ophthalmic-gel","indication":"Dry eye disease (keratoconjunctivitis sicca)","status":"phase_3"},{"name":"Cyclosporine ophthalmic gel vehicle","genericName":"Cyclosporine ophthalmic gel vehicle","slug":"cyclosporine-ophthalmic-gel-vehicle","indication":"Dry eye disease (keratoconjunctivitis sicca)","status":"phase_3"},{"name":"Hypromellose Eye Drops","genericName":"Hypromellose Eye Drops","slug":"hypromellose-eye-drops","indication":"Dry eye syndrome / keratoconjunctivitis sicca","status":"marketed"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"Betaxolol eye drops","genericName":"Betaxolol eye drops","slug":"betaxolol-eye-drops","indication":"Open-angle glaucoma","status":"phase_3"},{"name":"Levobetaxolol eye drops","genericName":"Levobetaxolol eye drops","slug":"levobetaxolol-eye-drops","indication":"Glaucoma","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"cardiovascular","drugs":[{"name":"CsA eye gel","genericName":"CsA eye gel","slug":"csa-eye-gel","indication":"Keratitis","status":"phase_2"},{"name":"Lower dose atropine sulfate eye drops","genericName":"Lower dose atropine sulfate eye drops","slug":"lower-dose-atropine-sulfate-eye-drops","indication":"Myopia progression control in children","status":"phase_3"}]}],"pipeline":[{"name":"Hypromellose Eye Drop","genericName":"Hypromellose Eye Drop","slug":"hypromellose-eye-drop","phase":"marketed","mechanism":"Hypromellose is a cellulose-based polymer that acts as an artificial tear lubricant, coating and protecting the ocular surface.","indications":["Dry eye syndrome / Keratoconjunctivitis sicca","Ocular surface protection and lubrication"],"catalyst":""},{"name":"Betaxolol eye drops","genericName":"Betaxolol eye drops","slug":"betaxolol-eye-drops","phase":"phase_3","mechanism":"Betaxolol is a selective beta-1 adrenergic receptor antagonist that reduces intraocular pressure by decreasing aqueous humor production in the eye.","indications":["Open-angle glaucoma","Ocular hypertension"],"catalyst":""},{"name":"CsA Ophthalmic Gel","genericName":"CsA Ophthalmic Gel","slug":"csa-ophthalmic-gel","phase":"phase_3","mechanism":"CsA (cyclosporine A) ophthalmic gel suppresses T-cell activation and reduces inflammatory cytokine production in the eye to treat dry eye disease.","indications":["Dry eye disease (moderate to severe)"],"catalyst":""},{"name":"CsA eye gel","genericName":"CsA eye gel","slug":"csa-eye-gel","phase":"phase_2","mechanism":"Calcineurin inhibitor","indications":["Keratitis","Uveitis"],"catalyst":""},{"name":"CsA-PG Ophthalmic Gel","genericName":"CsA-PG Ophthalmic Gel","slug":"csa-pg-ophthalmic-gel","phase":"phase_3","mechanism":"CsA-PG is a cyclosporine A prodrug formulated as an ophthalmic gel that suppresses local immune responses in the eye to treat dry eye disease.","indications":["Dry eye disease (keratoconjunctivitis sicca)"],"catalyst":""},{"name":"Cyclosporine ophthalmic gel vehicle","genericName":"Cyclosporine ophthalmic gel vehicle","slug":"cyclosporine-ophthalmic-gel-vehicle","phase":"phase_3","mechanism":"Cyclosporine is a calcineurin inhibitor that suppresses T-cell activation and reduces inflammatory cytokine production in the eye.","indications":["Dry eye disease (keratoconjunctivitis sicca)","Ocular surface inflammation"],"catalyst":""},{"name":"Hypromellose Eye Drops","genericName":"Hypromellose Eye Drops","slug":"hypromellose-eye-drops","phase":"marketed","mechanism":"Hypromellose is a cellulose-based polymer that acts as an artificial tear lubricant, coating and protecting the ocular surface.","indications":["Dry eye syndrome / keratoconjunctivitis sicca","Ocular surface lubrication and protection"],"catalyst":""},{"name":"Levobetaxolol eye drops","genericName":"Levobetaxolol eye drops","slug":"levobetaxolol-eye-drops","phase":"phase_3","mechanism":"Levobetaxolol is a selective beta-1 adrenergic receptor antagonist that reduces intraocular pressure by decreasing aqueous humor production in the eye.","indications":["Glaucoma","Ocular hypertension"],"catalyst":""},{"name":"Lower dose atropine sulfate eye drops","genericName":"Lower dose atropine sulfate eye drops","slug":"lower-dose-atropine-sulfate-eye-drops","phase":"phase_3","mechanism":"Low-dose atropine competitively blocks muscarinic acetylcholine receptors in the eye to slow myopia progression.","indications":["Myopia progression control in children"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMirwJBVV95cUxNS2psYWNHa21ZM3JFMFh3eUJfdHMxMTVTc0RRemh1ZmlMLTRpY0VnRXFfVUExbWZmMXNlVXlCV0xVRU5GNUcwNTVLb0ZGb1UxdGxhWEhFT3ItalEtX09DOWZPU0FvNjZNVEdQSUpIb01DZU5KUk00TE5mTEJwYjR5STV4WTVEQWs0WDhEVnFnN1pBbXdfR0JwcFRCNVIyNUZPWmpDRHdqU094cFd3Nm11MDJHRS1NYmFBY3NOd0pvaWxEdkJzWUxUSjZaTnhuYjVmVkY2R2FDUzQ2R1dmVlR1SURtQld5X2RkcVcyRk95Vm5mX092a2hhbmR3bVFnNG9EWDJGVU4yWFRfbGRuX2xDZG5VdUQ0aEtOVUs4MU83WkMwaGRxbnlpc2o0bG5ZWjg?oc=5","date":"2025-11-05","type":"pipeline","source":"businesswire.com","summary":"Tenpoint Therapeutics Ltd. Announces Submission of a New Drug Application for BRIMOCHOL™ PF for the Treatment of Presbyopia to the MFDS in South Korea - businesswire.com","headline":"Tenpoint Therapeutics Ltd. Announces Submission of a New Drug Application for BRIMOCHOL™ PF for the Treatment of Presbyo","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxOR1k5ckxWZTBkem5UOFNuSnVZYXR6WGYwWlZ2WVd0Wlp6T29maXg1Z2dZOFYyUkxXd0g3YkhYY08zazBYLUZYcS1HbndETjFnSXQwRnR0TWxuR3VIS1BnNk1XMjVQNlRXdFRUM0VHWVk5NHo1c3g4M292RUcxNHlJbV9SWnVkVnVvUmxpbkdnT2s3NXQ4ZExQdGZJOE45d2ktNHUzZw?oc=5","date":"2025-07-15","type":"pipeline","source":"Contract Pharma","summary":"Zhaoke, Fareva Ink Manufacturing MOA - Contract Pharma","headline":"Zhaoke, Fareva Ink Manufacturing MOA","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgJBVV95cUxNSjZzb2xCMUxoMzBoM1Y2WU5uUm9oY1NUS2VVdUZLZG5MYkhGMC1kQTNPZ3pVOUFxY0x5Nnp4aENsTGpldkdMU3UtUlJIdWY5RmNFQUJrNThSQmlMcnVybTlscVpKWFVoTmhnclZ3aWczMWxtczI3TThlUmRfUW5Tc1ZKeWlYSXlBTXNueHotV3NkendzeXduVGlPTlFIR3Qzd0xCUU9EU29pNkRZZmpFZXJxV05TcTBBUmk5cHF6ZDdrUEE3bnFlRGk0aWVtOVpsVkZmWXVCSV9HQ2NwN3JKLWF3blE0U0pTaVpfWUhBNjNtU1drTUE1OWh2bzQ2V2NDNUtnWU1XMDVOcV9sU1VnT0Q4OXhpLUdXT3c?oc=5","date":"2022-10-27","type":"trial","source":"GlobeNewswire","summary":"Vyluma Announces Positive Results From Phase III CHAMP - GlobeNewswire","headline":"Vyluma Announces Positive Results From Phase III CHAMP","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiWkFVX3lxTE9sUjBwWjBoR0d6WEVWYWFIRk0tMTE5U3JQZjB0cWZlUEhRN3lHQ1JWdHlQNE1HOXEzRjN6VnhQOV9HNXBadHd0UUxGcmhFSnRKTDhBSktyc1ROQQ?oc=5","date":"2021-04-28","type":"pipeline","source":"TradingView","summary":"6622 Stock Price and Chart — HKEX:6622 - TradingView","headline":"6622 Stock Price and Chart — HKEX:6622","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7wFBVV95cUxNcHZRT2ttQ2hTYlltOVRjeDNKREl3d3JNUW9Cb0NIT1lPemZaVXViVGs4a29PRTJESk54SUR6N3l5bFFiazlEVlp6UXQzMHRMdloxU2tmOG1seWFrckhINnhfVFJWU0w4VUE0T1VBQjUycjRUNzdJT21rczdMVUlneWZWeGl4UGZnbVFOdWRfaWFDcUJwWHpPelhIckRaZ1NpczRsRE9CbVF5WUp1V2R5WFRHOFhMNEpaTlU2bWh5cmtRczlSejlGUVliOGg5S0pLTmltVUJsck43SEU2aWMzZDF1ZHFPZHVRb0t6VWdMdw?oc=5","date":"2017-01-05","type":"pipeline","source":"prnewswire.com","summary":"TOT BIOPHARM and LEE'S PHARM Signed an Exclusive Licensing Agreement on Monoclonal Antibody Drug TAB014 - prnewswire.com","headline":"TOT BIOPHARM and LEE'S PHARM Signed an Exclusive Licensing Agreement on Monoclonal Antibody Drug TAB014","sentiment":"neutral"}],"patents":[],"drugCount":9,"phaseCounts":{"marketed":2,"phase_3":6,"phase_2":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}